Strategic Intelligence: Navigating shifts in pharmaceutical patent litigation
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
CRA has assisted clients in intellectual property (IP) matters concerning products and services in the life sciences sector, including Hatch-Waxman and BPCIA matters. We have also addressed patent, trademark, and copyright infringement, trade secret misappropriation, and IP licensing. Our experts have quantified damages based on lost profit and reasonable royalty methods and provided opinions on irreparable harm. In addition, we have experience addressing other forms of relief, such as rescission and disgorgement.
Our understanding of the unique dynamics of different therapeutic areas informs assessments of commercial success as a secondary indicator of non-obviousness and the claimed nexus between patented technologies and product success.
Engagements
- 01Achieving tax certainty for complex collaborations in the life sciences industryConsequently, complex risk-sharing transactions, such as joint ventures, co-development agreements, collaboration agreements, platform partnerships, licensing...View engagement
- 02Quasi-experimental econometric analyses in contract breach, theft of trade secrets, and tortious interference matterTo estimate damages associated with the tortious interference claims, CRA experts conducted a variety of econometric analyses. Quasi-experimental regression...View engagement
- 03Damages due to misappropriation of trade secrets and confidential information by multiple partiesCRA calculated actual loss, reasonable royalty damages, and unjust enrichment due to the plaintiff. Dr. Gregory K Bell provided opening and reply reports and...View engagement